<?xml version="1.0" encoding="UTF-8"?>
<p id="p0010">People travel abroad for many reasons, to experience new places, to relax, to visit friends and relatives, for business opportunities, and for work. More and more people are traveling globally; in 2017 there were approximately 1.3Â billion international tourist arrivals worldwide [
 <xref rid="bib1" ref-type="bibr">1</xref>]. This growth in international travel has occurred alongside the rise of biologic drugs and other therapies for autoimmune diseases such as Janus kinase (JAK) inhibitors, as well as other forms of immunosuppression used for solid organ transplantation and treatment for malignancies. These treatments mean that those living with chronic or previously untreatable conditions are now experiencing a much-improved quality of life. Whereas previously they might have been too unwell to travel they are now able to visit a wide range of destinations and enjoy a variety of activities. Research has shown that immunosuppressed travelers follow similar travel itineraries to nonimmunocompromised travelers and around a third visit countries with low human development indices [
 <xref rid="bib2" ref-type="bibr">2</xref>]. The convergence of these trends means that there is a growing population of immunosuppressed travelers with specific travel health needs.
</p>
